Potential contributions of viral envelope and host genetic factors in a human immunodeficiency virus type 1-infected long-term survivor

被引:9
|
作者
Grovit-Ferbas, K
Ferbas, J
Gudeman, V
Sadeghi, S
Goetz, MB
Giorgi, JV
Chen, ISY
O'Brien, WA
机构
[1] Univ Calif Los Angeles, Sch Med, Dept Med, Div Hematol Oncol, Los Angeles, CA 90095 USA
[2] Univ Calif Los Angeles, Sch Med, Dept Microbiol & Immunol, Los Angeles, CA 90095 USA
[3] Univ Calif Los Angeles, AIDS Inst, Los Angeles, CA 90095 USA
[4] Vet Adm Med Ctr, Los Angeles, CA 90073 USA
关键词
D O I
10.1128/JVI.72.11.8650-8658.1998
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The Lack of clinical progression in some individuals despite prolonged human immunodeficiency virus type 1 (HIV-1) infection may result from infection with less-pathogenic viral strains. To address this question, we examined the IIIV-1 en;elope protein from a donor with a low viral burden, stable CD4(+) T-lymphocyte counts, and little evidence of CD8(+) T-cell expansion, activation, or immune activity. To avoid potential changes in envelope function resulting from selection in vitro, envelope clones were constructed by using viral RNA isolated from uncultured peripheral blood mononuclear cells (PBMC). The data showed that recombinant viruses containing envelope sequences derived from RNA isolated from patient PBMC replicated poorly in primary CD4(+) T cells but demonstrated efficient growth in macrophages. The unusual phenotype of these viruses could not be explained solely by differential utilization of coreceptors since the chimeric viruses, as well as an uncloned isolate obtained from the same visit date, can utilize CCR5. In addition, the donor's own cells appeared resistant to infection with chimeric viruses containing autologous envelope sequences. Genotype analysis revealed that the donor was heterozygous for the previously described 32-bp deletion in CCR5 which may be linked with prolonged survival in IIIV-1-infected individuals. These data suggest that the changes in envelope sequences confer properties of viral attenuation, which together with the CCR5 +/Delta 32 genotype could account for the long-term survival of this patient.
引用
收藏
页码:8650 / 8658
页数:9
相关论文
共 50 条
  • [41] Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates
    Mirochnick, M
    Fenton, T
    Gagnier, P
    Pav, J
    Gwynne, M
    Siminski, S
    Sperling, RS
    Beckerman, K
    Jimenez, E
    Yogev, R
    Spector, SA
    Sullivan, JL
    JOURNAL OF INFECTIOUS DISEASES, 1998, 178 (02): : 368 - 374
  • [42] Osteonecrosis of the femoral head in a human immunodeficiency virus type 1-infected patient with lipodystrophy
    Tsai, YC
    Liu, CH
    Liao, CH
    Chen, MY
    Hung, CC
    JOURNAL OF THE FORMOSAN MEDICAL ASSOCIATION, 2002, 101 (03) : 210 - 213
  • [43] Pulmonary Mycobacterium sherrisii infection in a human immunodeficiency virus type 1-infected patient
    Gämperli, A
    Bosshard, PP
    Sigrist, T
    Brändli, O
    Wildermuth, S
    Weber, R
    Mueller, NJ
    JOURNAL OF CLINICAL MICROBIOLOGY, 2005, 43 (08) : 4283 - 4285
  • [44] Pharmacokinetics, safety, and activity of nevirapine in human immunodeficiency virus type 1-infected children
    Luzuriaga, K
    Bryson, Y
    McSherry, G
    Robinson, J
    Stechenberg, B
    Scott, G
    Lamson, M
    Cort, S
    Sullivan, JL
    JOURNAL OF INFECTIOUS DISEASES, 1996, 174 (04): : 713 - 721
  • [45] Effects of malaria infection in human immunodeficiency virus type 1-infected Ugandan children
    Kalyesubula, I
    MusokeMudido, P
    Marum, L
    Bagenda, D
    Aceng, E
    Ndugwa, C
    Olness, K
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1997, 16 (09) : 876 - 881
  • [46] Entamoeba gingivalis in human immunodeficiency virus type 1-infected patients with periodontal disease
    Lucht, E
    Evengård, B
    Skott, J
    Pehrson, P
    Nord, CE
    CLINICAL INFECTIOUS DISEASES, 1998, 27 (03) : 471 - 473
  • [47] Role of the human immunodeficiency virus type 1 envelope gene in viral fitness
    Rangel, HR
    Weber, J
    Chakraborty, B
    Gutierrez, A
    Marotta, ML
    Mirza, M
    Kiser, P
    Martinez, MA
    Este, JA
    Quiñones-Mateu, ME
    JOURNAL OF VIROLOGY, 2003, 77 (16) : 9069 - 9073
  • [48] Pharmacokinetics of the protease inhibitor indinavir in human immunodeficiency virus type 1-infected children
    Burger, DM
    van Rossum, AMC
    Hugen, PWH
    Suur, MH
    Hartwig, NG
    Geelen, SPM
    Scherpbier, HJ
    Hoetelmans, RMW
    Vulto, AG
    de Groot, R
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (03) : 701 - 705
  • [49] STREPTOCOCCUS-PNEUMONIAE IN HUMAN-IMMUNODEFICIENCY-VIRUS TYPE 1-INFECTED CHILDREN
    GESNER, M
    DESIDERIO, D
    KIM, M
    KAUL, A
    LAWRENCE, R
    CHANDWANI, S
    POLLACK, H
    RIGAUD, M
    KRASINSKI, K
    BORKOWSKY, W
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 1994, 13 (08) : 697 - 703
  • [50] Autoreactive cytotoxic T lymphocytes in human immunodeficiency virus type 1-infected subjects
    Veronese, FD
    Arnott, D
    Barnaba, V
    Loftus, DJ
    Sakaguchi, K
    Thompson, CB
    Salemi, S
    Mastroianni, C
    Sette, A
    Shabanowitz, J
    Hunt, DF
    Appella, E
    JOURNAL OF EXPERIMENTAL MEDICINE, 1996, 183 (06): : 2509 - 2516